DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, has launched InnoSyn route scouting services, a focused and flexible stand-alone system designed to significantly cut costs by the reduction of synthesis steps or redesign of synthesis routes.

The InnoSyn route scouting team supports R&D and the implementation of economical and scalable routes, with solutions that result from integrating DSM competencies such as biocatalysis, homogeneous catalysis, organic synthesis, and continuous chemistry. According to the company, these capabilities to rapidly screen a wide variety of catalysts speed up feasibility studies for chemocatalytic and biocatalytic steps.

Oliver May, Ph.D., business manager of InnoSyn route scouting services, commented, “DSM is recognized as a reliable and leading large scale cGMP manufacturer for registered intermediates and active pharmaceutical ingredients. This remains our focus but we also want to continuously serve changing customer needs whenever DSM can provide real value. Due to the reduced focus and resources in process R&D within our customers’ operations there is an increasing demand for developing flexible and robust ‘technology packages’ ready to implement at large scale. The new DSM InnoSyn route scouting services are setup to address exactly this specific need based on DSM’s broad and unique technology toolbox.”